Robert Repella Net Worth

The estimated Net Worth of Robert Repella is at least $1.83 Million dollars as of 19 November 2013. Robert Repella owns over 107,500 units of Biohaven Ltd stock worth over $535,800 and over the last 13 years Robert sold BHVN stock worth over $1,293,225.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Robert Repella BHVN stock SEC Form 4 insiders trading

Robert has made over 1 trades of the Biohaven Ltd stock since 2013, according to the Form 4 filled with the SEC. Most recently Robert sold 107,500 units of BHVN stock worth $1,293,225 on 19 November 2013.

The largest trade Robert's ever made was selling 107,500 units of Biohaven Ltd stock on 19 November 2013 worth over $1,293,225. On average, Robert trades about 15,357 units every 0 days since 2011. As of 19 November 2013 Robert still owns at least 15,000 units of Biohaven Ltd stock.

You can see the complete history of Robert Repella stock trades at the bottom of the page.

What's Robert Repella's mailing address?

Robert's mailing address filed with the SEC is 9605 MEDICAL CENTER DRIVE, SUITE 300, , ROCKVILLE, MD, 20850.

Insiders trading at Biohaven Ltd

Over the last 8 years, insiders at Biohaven Ltd have traded over $8,186,598,135 worth of Biohaven Ltd stock and bought 8,852,002 units worth $137,738,037 . The most active insiders traders include Robert J Hugin, John W Childs, and Declan Doogan. On average, Biohaven Ltd executives and independent directors trade stock every 14 days with the average trade being worth of $2,840,776. The most recent stock trade was executed by John W Childs on 18 July 2024, trading 28,400 units of BHVN stock currently worth $1,013,028.

What does Biohaven Ltd do?

Complete history of Robert Repella stock trades at Vanda Pharmaceuticals Inc and Biohaven Ltd

Biohaven Ltd executives and stock owners

Biohaven Ltd executives and other stock owners filed with the SEC include:

• Vlad Coric,
  Chief Executive Officer, Director
• William Jones,
  Chief Commercial Officer, Migraine and Common Diseases
• Charles Conway,
  Chief Scientific Officer
• Kimberly Gentile,
  Senior Vice President - Clinical Operations
• James Engelhart,
  Chief Financial Officer, Treasurer
• Elyse Stock,
  Chief Medical Officer
• John Tilton,
  Chief Commercial Officer, Rare and Orphan Diseases
• Dr. Vladimir Coric M.D.,
  Chairman, CEO & Pres
• William Jones M.B.A.,
  Chief Commercial Officer of Migraine & Common Diseases
• Julia Gregory,
  Independent Director
• John Childs,
  Director
• Gregory Bailey,
  Director
• Dr. Elyse Stock M.D.,
  Chief Medical Officer
• Kimberly Gentile,
  Sr. VP of Clinical Operations
• Robert Berman,
  Lead - Special Projects and Medical Oversight
• Robert Hugin,
  Director
• Michael Heffernan,
  Director
• Thomas Lynch,
  Chairman of the Board
• Clifford Bechtold M.S.,
  Pres & GM of Biohaven Ireland and Chief Compliance Officer
• Wendy Goss,
  Exec. Admin. Assistant
• Dr. Charles Conway,
  Chief Scientific Officer
• George C. Clark,
  VP & Chief Accounting Officer
• Matthew DeLawder,
  Director of Accounting
• Matthew Buten,
  Chief Financial Officer
• Albert Cha,
  Director
• Robert Repella,
  Director
• Eric Aguiar,
  
• Biotech Inc. Portage,
  
• Declan Doogan,
  
• Irina Antonijevic,
  
• Kishan Mehta,
  
• George C. Clark,
  VP, Chief Accounting Officer
• Matthew Buten,
  Chief Financial Officer
• Pharmaceutical Holding Co L...,
  
• Bruce Car,
  Chief Scientific Officer